Important Safety Information | Prescribing Information | Indications and Usage | Medical Information | Report An Adverse Event
Important Safety Information
Prescribing Information | Indications & Usage
Medical Information | Report An Adverse Event
Support Icon

Contact a Recordati Rare
Diseases Representative

For U.S. Healthcare Professionals For U.S. Patients
Important Safety Information Prescribing Information Indications and Usage
Support Icon

Contact a Recordati Rare
Diseases Representative

Quick Reference Guide For Healthcare Professionals

Dosing and Administration
How to Order
How Panhematin Works
Resources for Patients
Access and Assistance

Dosing and Administration

Dosing & Administration Guide
Return to Menu

How to Order

Contact your primary wholesaler or ASD Healthcare

Orders placed Monday-Thursday by 6:30 PM central time:

  • Sent UPS Next Day Air Saver for mid-afternoon delivery

Orders placed Friday by 6:00 PM central time:

  • Sent UPS Next Day Air Saver for Monday mid-afternoon delivery
  • For next day delivery, Saturday delivery must be requested

Earlier, same day, and weekend delivery is available with an additional shipping cost

Include any specific delivery instructions when ordering.

Return to Menu

How Panhematin Works

AIP Attack Cycle
Return to Menu

Resources for Patients

AIP Attack Plan

This interactive PDF allows you and your patient to enter in critical information, such as names and numbers of healthcare providers as well as friends and family members who can provide assistance, and much more.

AIP Attack Plan

AIP Medical Emergency Letter

This digital letter allows you and your patient to fill out in case you are being treated for an AIP attack by a healthcare provider who is unfamiliar with AIP and its treatment. Use the QR code to carry it on your mobile device.

AIP Medical Emergency Letter

DOWNLOAD TO YOUR PHONE:
AIP Medical Emergency Letter

Instructional video: How to add the AIP Medical Emergency Letter to a mobile device

Return to Menu

Access and Assistance

The Recordati Rare Diseases Patient Support Program provides:

  • Reimbursement support — Assisting with inquiries regarding coverage and reimbursement as they relate to PANHEMATIN
  • Copay assistance — Assisting eligible patients who receive PANHEMATIN infusions in outpatient care settings with their insurance copays
  • Patient Assistance Program (PAP) — Assisting qualified uninsured and underinsured patients with gaining access to PANHEMATIN

Contact the Recordati Rare Diseases Patient Support Program for Assistance

Monday-Friday between 9:00 a.m. and 5:00 p.m. ET.

Phone: 866-209-7604  Fax: 866-209-7599

Return to Menu

Indications And Usage

PANHEMATIN® is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.

Limitations of Use

  • Before administering PANHEMATIN, consider an appropriate period of carbohydrate loading (i.e., 400 g glucose/day for 1 to 2 days).
  • Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. PANHEMATIN therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration. PANHEMATIN is not effective in repairing neuronal damage.

Indications and Important
Safety Information

+ See More

Indications And Usage

PANHEMATIN® is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.

Important Safety Information

  • Do not use in patients with known hypersensitivity to PANHEMATIN.
  • Phlebitis is possible. Utilize a large arm vein or a central venous catheter for administration to minimize the risk of phlebitis.
  • Elevated iron and serum ferritin may occur. Monitor iron and serum ferritin in patients receiving multiple administrations of PANHEMATIN.
  • PANHEMATIN has transient and mild anticoagulant effect. Avoid concurrent anticoagulant therapy.
  • Reversible renal shutdown has been observed with an excessive hematin dose (12.2 mg/kg in a single infusion). Strictly follow recommended dosage guidelines.
  • PANHEMATIN may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
  • Most common adverse reactions in >1% of patients are headache, pyrexia, infusion site reactions, and phlebitis.
  • To report SUSPECTED ADVERSE EFFECTS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • Avoid CYP inducing drugs such as estrogens, barbituric acid derivatives and steroid metabolites which induce δ‑aminolevulinic acid synthetase 1 (ALAS1) through a feedback mechanism.
For more information, please see PANHEMATIN Full Prescribing Information at www.recordatirarediseases.com.

Important Safety Information

You are about to leave the PANHEMATIN.com website and enter a website operated by an independent third party. The links to third-party websites contained on PANHEMATIN.com are provided solely for your convenience. Recordati Rare Diseases does not control the opinions, claims or comments contained on any third-party website linked to PANHEMATIN.com, and your activities at those websites will be governed by the policies and practices of those third parties.

OK to proceed to third-party website CANCEL to return to PANHEMATIN.com